Finance

Lists
4016:TADAWUL
Middle East Pharmaceutical Industries Co
SAR 61,70
-0,32%
(-0,20) 1D
14 Okt., 15:15:44 GMT+3  ·   SAR
All symbols
SymbolPriceChange% Change
Generating top insights for 4016...
Open
SAR 61,70
High
SAR 62,70
Low
SAR 61,70
Mkt. cap
2,16 mjd
Avg. vol.
57,53 k
Volume
34,40 k
Dividend
2,52%
Quarterly dividend
SAR 0,39
Ex-dividend date
02 Sep. 2026
P/E ratio
19,90
52-wk high
SAR 79,10
52-wk low
SAR 53,90
EPS
SAR 3,10
Shares outstanding
21,55 m
No. of employees
731
Open
SAR 61,70
High
SAR 62,70
Low
SAR 61,70
Mkt. cap
2,16 mjd
Avg. vol.
57,53 k
Volume
34,40 k
Dividend
2,52%
Quarterly dividend
SAR 0,39
Ex-dividend date
02 Sep. 2026
P/E ratio
19,90
52-wk high
SAR 79,10
52-wk low
SAR 53,90
EPS
SAR 3,10
Shares outstanding
21,55 m
No. of employees
731
News stories
From web sources and news partners
About Middle East Pharmaceutical Industries Co
CEOMohamed Maher Al Ghannam
Employees731
Founded1998
HeadquartersRiaad, Riyadh Province, Saoedi-Arabië
SectorPharmaceutical industry
Websiteavalonpharmaceutical.com
Previous reportsAll values in SAR
Loading Previous Earnings...
Revenue
Net income
All values in SAR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
107,95 m
137,52 m
130,13 m
136,48 m
Cost of goods sold
45,81 m
47,32 m
49,78 m
51,36 m
Cost of revenue
45,81 m
47,32 m
49,78 m
51,36 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
50,78 m
43,26 m
48,09 m
51,16 m
Operating expense
51,48 m
43,77 m
50,05 m
51,43 m
Total operating expenses
97,29 m
91,08 m
99,83 m
102,79 m
Operating income
10,66 m
46,43 m
30,30 m
33,70 m
Other non operating income
-
-
-
-
EBT including unusual items
9,82 m
45,93 m
29,13 m
30,82 m
EBT excluding unusual items
9,82 m
45,89 m
29,13 m
30,82 m
Income tax expense
1,54 m
1,41 m
2,23 m
2,01 m
Effective tax rate
15,69%
3,07%
7,67%
6,54%
Other operating expenses
-147,78 k
-109,44 k
-54,06 k
-268,26 k
Net income
8,28 m
44,52 m
26,90 m
28,80 m
Net profit margin
7,67%
32,38%
20,67%
21,10%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
-
Interest expense
-844,49 k
-562,26 k
-1,16 m
-2,88 m
Net interest expenses
-844,49 k
-562,26 k
-1,16 m
-2,88 m
Depreciation and amortization charges
-
-
-
-
EBITDA
13,78 m
49,70 m
33,47 m
37,11 m
Gain or loss from assets sale
-40,87 k
-55,44 k
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme